What is the role of Positron Emission Tomography (PET) scan in detecting breast cancer metastasis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 15, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

PET scans, specifically 2-[18F]FDG PET/CT, are highly recommended for detecting breast cancer metastasis, particularly in monitoring treatment response and assessing bone metastases, due to their high sensitivity and ability to detect distant metastases earlier than conventional imaging modalities 1.

Key Points to Consider

  • The joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer suggests that 2-[18F]FDG PET/CT may play a role in monitoring treatment response in metastatic breast cancer, with a high level of evidence and agreement 1.
  • The guideline also highlights the usefulness of 2-[18F]FDG PET/CT in assessing bone metastases and enabling early response to treatment evaluation, with a 100% level of evidence and agreement 1.
  • Several studies have demonstrated the superiority of 2-[18F]FDG PET/CT over conventional imaging modalities, such as CT and bone scans, in detecting distant metastases and assessing treatment response 1.

Procedure and Limitations

  • The procedure involves injecting a radioactive tracer, typically F-18 fluorodeoxyglucose or FDG, which accumulates in cancer cells due to their higher metabolic activity.
  • Patients must fast for 4-6 hours before the scan, avoid strenuous exercise for 24 hours prior, and maintain normal hydration.
  • The entire procedure takes about 2-3 hours, with the actual scanning lasting 20-30 minutes.
  • PET scans have limitations, including false positives from inflammation or infection, and false negatives from small lesions or slow-growing cancers.

Clinical Application

  • PET scans are most effective when used in conjunction with other imaging modalities, such as MRI or bone scans, for comprehensive staging and treatment planning.
  • The use of 2-[18F]FDG PET/CT can lead to changes in clinical stage and treatment planning, particularly in patients with stage IIIB and operable IIIA tumors, and those with specific tumor subtypes, such as invasive ductal cancers, ER-negative and triple-negative tumors, high-grade malignancies, and those with p53 mutations 1.

From the Research

Detection of Breast Cancer Metastasis using PET Scan

  • The use of PET scans, particularly [18F]FDG PET/MRI and [18F]FDG PET/CT, has been shown to be effective in detecting bone metastases in breast cancer patients 2, 3, 4.
  • A study published in 2021 found that [18F]FDG PET/MRI and MRI alone were able to detect all patients with histopathologically proven bone metastases, with a sensitivity and specificity of 100% 2.
  • Another study published in 2013 noted that FDG-PET provides accurate diagnostic information as a whole-body imaging modality in staging of breast cancer patients, particularly in detecting distant metastases 3.
  • A meta-analysis published in 2023 compared the diagnostic efficacy of [18F]FDG PET/CT and [18F]FDG PET/MRI in detecting bone metastases in breast cancer patients, and found that [18F]FDG PET/MRI had a higher sensitivity than [18F]FDG PET/CT 4.

Comparison with Other Imaging Modalities

  • [18F]FDG PET/MRI and MRI alone were found to be significantly better than CT and bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer 2.
  • CT was found to be superior in detecting small lung metastases, while bone scintigraphy was superior in detecting osteoblastic disease 3.
  • FDG-PET/CT was found to be useful for initial staging of breast cancer, particularly in detecting extra-axillary lymph nodes and distant metastases 5, 6.

Clinical Applications

  • The use of FDG-PET/CT in breast cancer staging has been recommended by the National Comprehensive Cancer Network (NCCN) guidelines, starting from stage IIIA 5.
  • A review published in 2021 recommended the use of FDG-PET/CT for initial staging of breast cancer, starting from clinical stage IIB, and possibly useful in patients with clinical stage IIA 6.

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

3
Research

Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2013

5
Research

The value of 18F-FDG PET/CT imaging in breast cancer staging.

Bosnian journal of basic medical sciences, 2018

6
Research

Breast cancer: initial workup and staging with FDG PET/CT.

Clinical and translational imaging, 2021

Related Questions

Can a patient scheduled for a bone scan undergo chemotherapy?
What is the next step in evaluating a patient with a large bone nodule lateral to the hallux (big toe) between it and the second toe?
What is more effective for a patient with a history of breast cancer and rib pain, a bone scan or a Positron Emission Tomography (PET) scan?
What is the diagnosis of a ring-enhancing lesion in the brain?
What are the diagnostic methods for Benign Prostatic Hyperplasia (BPH)?
What are all the imaging studies that can be performed in the Hepatopancreaticobiliary (HPB) system and when should each be done?
What are the imaging studies for Benign Prostatic Hyperplasia (BPH) and when should each be performed?
What DSM diagnosis is appropriate for an individual with restrictive eating and emotional binge eating, but without identified Binge Eating Disorder (BED)?
At what International Prostate Symptom Score (IPSS) should medical treatment be initiated for Benign Prostatic Hyperplasia (BPH)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question